Intensified blood-pressure control reduced the risk of a 50% decline in GFR or progression to end-stage renal disease compared to conventional control (29.9% vs 41.7%; HR 0.65; 95% CI 0.44-0.94; P=0.02).
RCT (n=385)
Does intensified blood-pressure control reduce the progression of renal failure in children with chronic kidney disease receiving high-dose ACE inhibitors?
Intensified blood-pressure control targeting a 24-hour mean arterial pressure below the 50th percentile significantly delays the progression of renal failure in children with chronic kidney disease.
Hazard Ratio: 0.65 (95% CI 0.44–0.94)
Absolute Event Rate: 29.9% vs 41.7%
p-value: p=0.02
BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion. RESULTS: A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P=0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease. CONCLUSIONS: Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.)
Wühl et al. (Wed,) conducted a rct in chronic kidney disease (n=385). Intensified blood-pressure control vs. Conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile) was evaluated on time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease (HR 0.65, 95% CI 0.44-0.94, p=0.02). Intensified blood-pressure control reduced the risk of a 50% decline in GFR or progression to end-stage renal disease compared to conventional control (29.9% vs 41.7%; HR 0.65; 95% CI 0.44-0.94; P=0.02).